Active Clinical Trials at OOS

All Clinical Trials

Adjuvant Wider

Tumor site:
Breast
Description:
A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2− early breast cancer.
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Novartis ; NCT Number: 05827081

ARTEMIDE-Lung02 (D702BC00001)

Tumor site:
Lung
Description:
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: AstraZeneca; NCT Number: NCT06692738

ARTEMIDE-Lung03 (D702FC00001)

Tumor site:
Lung
Description:
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: AstraZeneca; NCT Number: NCT06627647

ASTX030-01

Tumor site:
Hematologic (MDS, CMML, AML)
Description:
A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Astex; NCT Number: NCT04256317

BF-1

Tumor site:
Lung
Description:
The purpose of this study is to collect and analyze blood samples for the evaluation of a novel cell-free DNA (cfDNA) fragmentation analysis platform. The platform utilizes machine learning algorithms to assess cfDNA fragmentation patterns and compare them to reference populations with and without cancer. This analysis aims to support the development and validation of a non-invasive method for early cancer detection and risk stratification.
Available at:
Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office
Notes:
Sponsor: ARI

B Stronger I (01-PS-001)

Tumor site:
Breast
Description:
Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
Available at:
Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Personalis; NCT Number: NCT06230185

BillionToOne (NS-002)

Tumor site:
Solid Tumors
Description:
Tumor methylation scores will be quantified at baseline across all tumor types to establish the clinical limit of detection of the assay. Associations between baseline tumor methylation score and PFS, OS, and disease control rate will be examined across therapeutic regimens and cancer types to test the hypothesis that the TMS is prognostic of outcome.
Available at:
Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office
Notes:
Study Sponsor: BillionToOne Inc.; IRB number: 20231272

Elegant (STML-ELA-0422)

Tumor site:
Breast
Description:
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-Positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence- A Global, Multicenter, Randomized, Open-Label Phase 3 study
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Stenline Therapeutics, Inc.; NCT Number: NCT05563220

Gilead

Tumor site:
Breast
Description:
This non-interventional study collects data to research about the perspectives and management of treatment side effects among patients with metastatic breast cancer. The main goal of this study is to understand how treatment side effects impact patients’ physical health, quality of life, and well-being.
Available at:
Our Salem Office
Notes:
Sponsor: Gilead Sciences ; Protocol Number: GS-US-569-6775

GEMINI

Tumor site:
Lung
Description:
TEMPUS GEMINI (TP-CA-002) NSCLC SURVEILLANCE STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)
Available at:
Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Tempus; IRB Number: NCT05236114

INTRINSIC

Tumor site:
Colorectal Cancer
Description:
A Phase I/Ib global, multicenter, open-label umbrella study evaluating the safety and efficacy of targeted therapies in subpopulations of patients with metastatic colorectal cancer
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Roche; NCT Number: NCT04929223

Mirati KRYSTAL 7

Tumor site:
Lung (NSCLC)
Description:
Phase 3 Trial of MRTX849 Plus Pembrolizumab for NSCLC With KRAS G12C Mutation (KRYSTAL-7)
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Mirati Therapeutics Inc; NCT Numer: NCT04613596

Ovation-23-001

Tumor site:
Breast; Lung
Description:
Collection of Biological Specimens and Associated Health Information for Secondary Research in Future Studies
Available at:
Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Ovation.io, Inc. NCT# NCT06369441
Page 1 of
Page: